



CONTACT:
Charles Robb
Chief Financial Officer
Corcept Therapeutics
650-688-8783
crobb@corcept.com
www.corcept.com

**CORCEPT THERAPEUTICS TO ANNOUNCE SECOND QUARTER FINANCIAL RESULTS
PROVIDE CORPORATE UPDATE AND HOST CONFERENCE CALL**

MENLO PARK, Calif., (August 2, 2018) – Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on August 9, 2018. The Company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).

Conference Call Information

To participate, dial 1-888-394-8218 from the United States or 1-323-794-2588 internationally approximately 10 minutes before the start of the call. The passcode is 6703650.

A replay will be available through August 23, 2018 at 1- 888-203-1112 from the United States and 1- 719-457-0820 internationally. The passcode will be 6703650.

About Corcept Therapeutics Incorporated

Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol. Korlym[®] is the company's first FDA-approved medication. Corcept has a large portfolio of proprietary compounds that modulate the effects of cortisol but not progesterone. Corcept owns extensive United States and foreign intellectual property covering the use of cortisol modulators in the treatment of a wide variety of serious disorders, including Cushing's syndrome. It also holds composition of matter patents covering its selective cortisol modulators.